107 related articles for article (PubMed ID: 28477317)
1. TP53 germline and somatic mutations in a patient with fibrolamellar hepatocellular carcinoma.
Andrade RC; de Lima MAFD; de Faria PAS; Vargas FR
Fam Cancer; 2018 Jan; 17(1):119-122. PubMed ID: 28477317
[TBL] [Abstract][Full Text] [Related]
2. Two TP53 germline mutations in a classical Li-Fraumeni syndrome family.
van Hest LP; Ruijs MW; Wagner A; van der Meer CA; Verhoef S; van't Veer LJ; Meijers-Heijboer H
Fam Cancer; 2007; 6(3):311-6. PubMed ID: 17318340
[TBL] [Abstract][Full Text] [Related]
3. TP53, MSH4, and LATS1 germline mutations in a family with clustering of nervous system tumors.
Kim YH; Ohta T; Oh JE; Le Calvez-Kelm F; McKay J; Voegele C; Durand G; Mittelbronn M; Kleihues P; Paulus W; Ohgaki H
Am J Pathol; 2014 Sep; 184(9):2374-81. PubMed ID: 25041856
[TBL] [Abstract][Full Text] [Related]
4. Identification of the
Sandoval RL; Masotti C; de Macedo MP; Ribeiro MFSA; Leite ACR; Meireles SI; Bovolin RM; Santini FC; Munhoz RR; Jardim DLF; Katz A; Camargo AA; Fernandes GDS; Achatz MI
JCO Glob Oncol; 2021 Jul; 7():1141-1150. PubMed ID: 34270331
[TBL] [Abstract][Full Text] [Related]
5. Clinical management of TP53 mosaic variants found on germline genetic testing.
Ward A; Farengo-Clark D; McKenna DB; Safonov A; Good M; Le A; Kessler L; Shah PD; Bradbury AR; Domchek SM; Nathanson KL; Powers J; Maxwell KN
Cancer Genet; 2024 Jun; 284-285():43-47. PubMed ID: 38677009
[TBL] [Abstract][Full Text] [Related]
6. Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants.
Fortuno C; Lee K; Olivier M; Pesaran T; Mai PL; de Andrade KC; Attardi LD; Crowley S; Evans DG; Feng BJ; Foreman AKM; Frone MN; Huether R; James PA; McGoldrick K; Mester J; Seifert BA; Slavin TP; Witkowski L; Zhang L; Plon SE; Spurdle AB; Savage SA;
Hum Mutat; 2021 Mar; 42(3):223-236. PubMed ID: 33300245
[TBL] [Abstract][Full Text] [Related]
7. A quantitative model to predict pathogenicity of missense variants in the TP53 gene.
Fortuno C; Cipponi A; Ballinger ML; Tavtigian SV; Olivier M; Ruparel V; Haupt Y; Haupt S; Study ISK; Tucker K; Spurdle AB; Thomas DM; James PA
Hum Mutat; 2019 Jun; 40(6):788-800. PubMed ID: 30840781
[TBL] [Abstract][Full Text] [Related]
8. The African-centric P47S Variant of
Stieg DC; Parris JLD; Yang THL; Mirji G; Reiser SK; Murali N; Werts M; Barnoud T; Lu DY; Shinde R; Murphy ME; Claiborne DT
Cancer Res Commun; 2023 Jul; 3(7):1200-1211. PubMed ID: 37441266
[TBL] [Abstract][Full Text] [Related]
9. A new therapeutic basis for treating Li-Fraumeni Syndrome breast tumors expressing mutated TP53.
Glazer RI
Oncotarget; 2010 Nov; 1(7):470-471. PubMed ID: 21317445
[No Abstract] [Full Text] [Related]
10. Li-Fraumeni Syndrome With Six Primary Tumors-Case Report.
Stojiljković D; Cvetković A; Jokić A; Mirčić D; Mihajlović S; Krivokuća A; Crnogorac MĐ; Glisic L
Case Rep Oncol Med; 2024; 2024():6699698. PubMed ID: 38765733
[TBL] [Abstract][Full Text] [Related]
11. Identification of TP53 germline variants in pediatric patients undergoing tumor testing: strategy and prevalence.
Luo M; Wong D; Zelley K; Wu J; Schubert J; Denenberg EH; Fanning EA; Chen J; Gallo D; Golenberg N; Patel M; Conlin LK; Maxwell KN; Wertheim GB; Surrey LF; Zhong Y; Brodeur GM; MacFarland SP; Li MM
J Natl Cancer Inst; 2024 May; ():. PubMed ID: 38702830
[TBL] [Abstract][Full Text] [Related]
12. A case series of non-small cell lung cancer patients with
Cognigni V; Capelletto E; Bordi P; Pavese V; Carfì FM; Gelsomino F; De Giglio A; Chiari R; Minari R; Ambrosini E; Percesepe A; Giachino D; Bironzo P; Tiseo M
Tumori; 2024 May; ():3008916241255485. PubMed ID: 38779904
[TBL] [Abstract][Full Text] [Related]
13. CASP9 germline mutation in a family with multiple brain tumors.
Ronellenfitsch MW; Oh JE; Satomi K; Sumi K; Harter PN; Steinbach JP; Felsberg J; Capper D; Voegele C; Durand G; McKay J; Le Calvez-Kelm F; Schittenhelm J; Klink B; Mittelbronn M; Ohgaki H
Brain Pathol; 2018 Jan; 28(1):94-102. PubMed ID: 27935156
[TBL] [Abstract][Full Text] [Related]
14. Hematologic malignancies in Li-Fraumeni syndrome: A case report.
Bundrant B; Gerstein Y; Arun B; DiNardo CD
Am J Med Genet A; 2024 Jul; 194(7):e63573. PubMed ID: 38410872
[TBL] [Abstract][Full Text] [Related]
15. Primary Axillary Vein Leiomyosarcoma in Li-Fraumeni Syndrome.
Roslly MZ; Omar N; Naim MS
Radiol Imaging Cancer; 2024 Jan; 6(1):e230184. PubMed ID: 38276907
[No Abstract] [Full Text] [Related]
16. Li-Fraumeni Syndrome in the Cancer Genomics Era.
Foulkes WD; Polak P
J Natl Cancer Inst; 2021 Nov; 113(12):1615-1617. PubMed ID: 34240211
[No Abstract] [Full Text] [Related]
17. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.
Bouaoun L; Sonkin D; Ardin M; Hollstein M; Byrnes G; Zavadil J; Olivier M
Hum Mutat; 2016 Sep; 37(9):865-76. PubMed ID: 27328919
[TBL] [Abstract][Full Text] [Related]
18. De novo germline TP53 mutation in a pediatric patient with Li-Fraumeni syndrome and diffuse peritoneal mesothelioma.
Ortaköylü MY; Özdemir Sİ; Dinçaslan H; Taçyıldız N; Ateş U; Ünal AE; Soydal Ç; Fitoz ÖS; Karabulut HG; Ruhi HI; Ünal EC
Pediatr Blood Cancer; 2024 May; ():e31071. PubMed ID: 38773723
[No Abstract] [Full Text] [Related]
19.
Kou SH; Li J; Tam B; Lei H; Zhao B; Xiao F; Wang SM
NAR Cancer; 2023 Sep; 5(3):zcad025. PubMed ID: 37304756
[No Abstract] [Full Text] [Related]
20. Mixed fibrolamellar hepatocellular carcinoma.
Limaiem F; Bouraoui S
Clin Case Rep; 2021 Jun; 9(6):e04318. PubMed ID: 34194803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
